Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PER2 | O15055 | 1/20 | 0.41 |
| ▸ | CRY1 | Q16526 | 1/20 | 0.41 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.41 |
| ▸ | CACNA1B | Q00975 | 3/20 | 0.41 |
| ▸ | RORC | P51449 | 9/20 | 0.40 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1924764 | 0.92 | PER2 (0.41) | PER2CRY1CRY2CACNA1BRORC | |
| SCHEMBL6900543 | 0.71 | EPHX2 (0.40) | SLC9A1ALDH1A1MAPT | |
| SCHEMBL1926954 | 0.70 | GPR119 (0.39) | RORCGPR119 | |
| SCHEMBL1926107 | 0.66 | KMT2A (0.39) | ALDH1A1MAPT | |
| SCHEMBL1925443 | 0.64 | KMT2A (0.41) | ALDH1A1 | |
| SCHEMBL20684183 | 0.63 | AOC3 (0.44) | PER2CRY1CRY2RORCALDH1A1 | |
| SCHEMBL11324303 | 0.63 | PER2 (0.41) | PER2CRY1CRY2ALDH1A1NPY5R | |
| SCHEMBL17689403 | 0.62 | HTR2A (0.55) | HTR2AHTR2C | |
| SCHEMBL4106320 | 0.62 | EPHX2 (0.57) | ALDH1A1GPR119 | |
| SCHEMBL7280301 | 0.62 | LTA4H (0.63) | RORCALDH1A1NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2509941-B1 | N-ACYLATED HYDROXYLAMINE DERIVATIVES AND O-ACYLATED HYDROXYLAMINE DERIVATIVES | UNIV JOHNS HOPKINS (US) | 2019-01-23 | — | — | EP | disclosed |
| US-20180050985-A1 | N-ACYLOXYSULFONAMIDE AND N-HYDROXY-N-ACYLSULFONAMIDE DERIVATIVES | THE JOHNS HOPKINS UNIVERSITY | 2018-02-22 | — | — | US | disclosed |
| US-20160046570-A1 | N-ACYLOXYSULFONAMIDE AND N-HYDROXY-N-ACYLSULFONAMIDE DERIVATIVES | THE JOHNS HOPKINS UNIVERSITY | 2016-02-18 | — | — | US | disclosed |
| US-20140235636-A1 | N-ACYLOXYSULFONAMIDE AND N-HYDROXY-N-ACYLSULFONAMIDE DERIVATIVES | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-20110144067-A1 | N-Acyloxysulfonamide and N-Hydroxy-N-Acylsulfonamide Derivatives | THE JOHNS HOPKINS UNIVERSITY | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235636-A1 | N-ACYLOXYSULFONAMIDE AND N-HYDROXY-N-ACYLSULFONAMIDE DERIVATIVES | TNNI3, TNNT2, TNNC1 | PER2 2678/4885CRY1 3289/4885CRY2 2559/4885 |
| US-20180050985-A1 | N-ACYLOXYSULFONAMIDE AND N-HYDROXY-N-ACYLSULFONAMIDE DERIVATIVES | TNNI3, TNNT2, NOS2 | PER2 2730/4885CRY1 3263/4885CRY2 2520/4885 |
| US-20160046570-A1 | N-ACYLOXYSULFONAMIDE AND N-HYDROXY-N-ACYLSULFONAMIDE DERIVATIVES | TNNI3, TNNT2, TNNC1 | PER2 2678/4885CRY1 3289/4885CRY2 2559/4885 |
| US-20110144067-A1 | N-Acyloxysulfonamide and N-Hydroxy-N-Acylsulfonamide Derivatives | TNNI3, TNNT2, TNNC1 | PER2 2678/4885CRY1 3289/4885CRY2 2559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.